Author

Kamal Nazzal

Institutions: EMD Serono, Inc. (United States), Merck Healthcare KGaA, Darmstadt (Germany)

Observed institutions: EMD Serono, Inc. (United States), Merck Healthcare KGaA, Darmstadt (Germany)

OpenAlex ID: A5075397173

A phase I dose-escalation trial of TH-302 with nab-paclitaxel and gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.

2015 · Anthony J. Olszanski, Andrea Wang-Gillam, et al. · Journal of Clinical Oncology · 1

Works count: 1

Citation count: 1

H-index: 1

I10-index: